Tier 4 — mechanistic

Therapeutic potential of quercetin to decrease blood pressure: review of efficacy and mechanisms

Larson AJ, Symons JD, Jalili T
Advances in Nutrition 2012 3(1):39-46

Bibliography

PubMed
PMID 22332099
PubMed Central
PMC3262612
DOI
10.3945/an.111.001271
Funding
Not reported in the available abstract/metadata.
Competing interests
Not reported in the available abstract/metadata.

Study snapshot

DesignNarrative review
ModelReview of animal and human quercetin supplementation studies
SampleNot applicable (review)
InterventionOral quercetin supplementation (various doses across reviewed studies)
DurationNot applicable (review)
EndpointsSystolic and diastolic blood pressure; Proposed mechanisms (nitric oxide, oxidative stress, ACE activity)

What the study showed, in plain terms

This is a review, not a new experiment. It summarises existing animal and human studies on quercetin, a flavonoid closely related to fisetin, and blood pressure. Its main conclusion is that more recent work in hypertensive animals and people (blood pressure above 140/90 mmHg) shows a blood pressure reduction after quercetin supplementation, with several plausible mechanisms discussed, including effects on nitric oxide signalling, oxidative stress, and angiotensin-converting enzyme activity. It is about quercetin, not fisetin, so it should be read as context for what a related flavonoid can do, not as direct evidence for fisetin itself.

Key findings

Reviewed evidence indicates that quercetin supplementation lowers blood pressure in hypertensive animal models and hypertensive human subjects, with a less consistent effect reported in normotensive subjects. The review discusses several proposed mechanisms, including improved nitric oxide bioavailability, reduced oxidative stress, and mild ACE-inhibitory activity, without settling on a single confirmed pathway.

What this study can and cannot tell us

This is a narrative review, not a new trial or meta-analysis with pooled effect sizes. It covers quercetin, not fisetin — related flavonoids can differ meaningfully in potency and pharmacokinetics, so any extrapolation to fisetin is an assumption, not a demonstrated effect.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability